PODDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

INSULET CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$141.96+0.86 (+0.61%)

Close on Oct 19, 2026

Market cap: $9.85B
P/E (TTM): 26.5
Dividend yield: –

Dividends

Insulet has not reported a dividend

No dividend per share appears in Insulet's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in Insulet's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PODD.

Revenue growth29.4% · median 4.0%

Gross margin71.1% · median 56.0%

Operating margin16.9% · median 3.3%

Net margin12.3% · median 1.4%

Company	Revenue	Growth
DXCM	$4.97B	+15.5%
MMED	$3.10B	+14.3%
PODD	$3.05B	+29.4%
ICUI	$2.16B	-9.0%
TNDM	$1.04B	+4.0%
EMBC	$1.02B	-7.6%

Company

Next earnings (est.): Nov 5, 2026, before open
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 5,400
Held by institutions: 100.0%
Auditor: GRANT THORNTON LLP
SEC CIK: 1145197

Advertisement
300 × 250